NASDAQ:AMIX • US05330T2050
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AUTONOMIX MEDICAL INC (AMIX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-17 | Maxim Group | Maintains | Buy -> Buy |
| 2025-04-29 | Maxim Group | Initiate | Buy |
| 2024-09-03 | Ladenburg Thalmann | Initiate | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | |||||
| EBITDA YoY % growth | N/A | N/A | -11.949M | -11.405M 4.55% | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.594M | -1.991M 85.36% | -12.03M -504.37% | -11.588M 3.67% | N/A -36.45% | N/A 2.81% | N/A -7.99% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A -77.46% | N/A 30.56% | N/A -16.00% |
All data in USD
| Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.52 71.54% | -0.45 58.06% | -0.61 55.65% | -0.57 -58.67% | -0.57 -11.29% | -0.48 -6.82% | -0.51 16.67% | -0.51 10.71% | -0.57 0.36% |
| Revenue Q2Q % growth | 102K | 255K | 561K | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.435M -5.62% | -3.921M -14.63% | 3.641M 148.33% | -3.713M -9.57% | -4.029M -17.30% | -3.835M 2.20% | -4.09M -212.34% | -4.08M -9.89% | -4.59M -13.92% |
All data in USD
8 analysts have analysed AMIX and the average price target is 5.2 USD. This implies a price increase of 1150.48% is expected in the next year compared to the current price of 0.416.
The consensus EPS estimate for the next earnings of AUTONOMIX MEDICAL INC (AMIX) is -0.52 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering AUTONOMIX MEDICAL INC (AMIX) is 8.